BNP Paribas Financial Markets
BCAX

BNP Paribas Financial Markets’s Bicara Therapeutics BCAX Stock Holding History

BNP Paribas Financial Markets’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.3M Buy
43,844
+3,448
+9% +$76.9K ﹤0.01% 3135
2026
Q1 		$803K Sell
40,396
-55,505
-58% -$955K ﹤0.01% 3285
2025
Q4 		$1.61M Buy
95,901
+59,385
+163% +$1.01M ﹤0.01% 2779
2025
Q3 		$577K Buy
36,516
+33,348
+1,053% +$373K ﹤0.01% 3470
2025
Q2 		$29.4K Sell
3,168
-18,349
-85% -$219K ﹤0.01% 4451
2025
Q1 		$280K Buy
21,517
+19,687
+1,076% +$261K ﹤0.01% 3526
2024
Q4 		$31.9K Buy
+1,830
New +$38.1K ﹤0.01% 4584

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BNP Paribas Financial Markets's BCAX Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Bicara Therapeutics (BCAX) stake by 8.5% in Q2 2026, buying an estimated $76.9K and bringing the position to 43,844 shares worth $1.3M. The position accounts for ﹤0.01% of the portfolio, ranked #3135.

BNP Paribas Financial Markets first reported a position in BCAX in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.61M in Q4 2025. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • BNP Paribas Financial Markets held 43,844 shares of Bicara Therapeutics worth $1.3M as of Q2 2026.
  • BNP Paribas Financial Markets bought 3,448 Bicara Therapeutics shares in Q2 2026, an estimated $76.9K.
  • Bicara Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3135 holding.
  • BNP Paribas Financial Markets first reported a position in Bicara Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • BNP Paribas Financial Markets's Bicara Therapeutics position peaked at $1.61M in Q4 2025.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.